Meningococcal vaccines

On this page you’ll find an overview of meningococcal vaccines, including what they are, who can get them and why they’re important. 

  • Meningococcal meningitis is the most common cause of bacterial meningitis globally and can have a devastating impact on families and individuals.
  • There are several different groups (serogroups), the six most common of which are A, B, C, W, X and Y.
  • Certain serogroups of meningococcal bacteria are more common in different parts of the world.
  • The vaccines available to you and your family will depend on where in the world you live.
  • Not all meningococcal disease is vaccine-preventable, but vaccines are available which protect against different serogroups.
  • Meningococcal vaccines are a safe and effective way to protect yourself and your family from illness caused by meningococcal bacteria.

What are meningococcal vaccines?

Meningococcal vaccines protect against disease caused by meningococcal bacteria. There are several groups (called serogroups) of meningococcal bacteria that can cause disease. The most common disease-causing groups around the world are A, B, C, W, X and Y.1 The risk of becoming unwell with one of these groups varies according to where in the world you live.

Read more about meningococcal meningitis.

Several vaccines are available to protect against different groups of meningococcal bacteria, and different combinations of groups. These include:

  • MenA
  • MenB
  • MenC
  • MenAC
  • MenACWY
  • MenABCWY
  • MenACWYX
Meningococcal vaccines work by introducing a harmless piece of the bacteria, called an antigen, into your body. This allows your immune system to recognise the bacteria and make protective antibodies against it. These antibodies then circulate in the bloodstream. If you encounter the bacteria you’ve been vaccinated against, your antibodies can destroy them before they can make you sick.

Many of the meningococcal vaccines available are known as conjugate vaccines. They are made from a small fragment of the sugar coating on the outside of the bacteria, joined to a harmless protein. Conjugate vaccines work well in children and provide long-lasting protection. They protect you from becoming unwell and also stop you from carrying the bacteria and passing it to others. This helps protect the wider population from the disease.
 
Some meningococcal vaccines are polysaccharide vaccines. This means they contain just the outer sugary coat of the bacteria. Unfortunately, these vaccines don’t work well in children. Also, they don’t stop you from carrying the bacteria and passing it to others.
 
The vaccines that protect against meningococcal group B (MenB) are protein vaccines. These vaccines contain proteins found on the surface of the bacteria. Like the other meningococcal vaccines, they trigger our immune system to produce antibodies that attack and fight off infection. The MenB vaccine provides protection against meningococcal disease, but doesn’t stop you from carrying the bacteria. So, like polysaccharide vaccines, they don’t prevent the bacteria being spread. 
 
If a meningococcal vaccine is available to you or your family through your country's national immunisation program, the type of vaccine you’re offered will depend on which groups are most common where you live.

Who can get meningococcal vaccines?

Unlike for some other meningitis vaccines, there is no global recommendation from the World Health Organization (WHO) for all countries across the world to have a meningococcal vaccination programme. People who live in an area of sub-Saharan Africa known as the meningitis belt are at much higher risk of becoming ill with this disease than those in other areas of the world. For this reason, the WHO have recommended that all countries in the meningitis belt introduce meningococcal vaccines into their immunisation schedule.2

Outside the meningitis belt, countries make decisions about whether to provide meningococcal vaccines by gathering and considering evidence on:

  • How common the disease is.
  • The expected impact of the vaccine.
  • The vaccine's cost.
These countries use vaccine experts to decide how to use meningococcal vaccines. They usually target people who are at the highest risk of becoming ill or who are at the highest risk of passing the disease on to others. So recommendations for the use of meningococcal vaccines tend to include:
 
  • Children under the age of five (who are usually at the highest risk of disease).
  • Sometimes teenagers (who are at increased risk of both getting the disease and passing the disease-causing bacteria to others).
Certain medical conditions can also increase your risk of meningococcal meningitis. Examples include asplenia or dysfunction of the spleen, complement disorders and immunosuppression (due to diseases like HIV or treatments like chemotherapy). If you have one of these conditions, you may be eligible to receive a vaccine no matter what age you are. Speak to a health professional about the vaccines available to you.
 
You can find out if meningococcal vaccines are part of your country’s national immunisation programme by checking the WHO's national immunisation schedule data portal.

In the UK and Ireland, the available vaccines that protect against meningococcal bacteria are:
 
  • MenACWY, which is offered to teenagers between 13-15 years of age.
  • Men B, which is offered to babies at 8 and 16 weeks with a booster aged one.
  • Men C, which is offered to children aged 12-13 months (as a combined MenC/Hib vaccine).
Vaccination against meningococcal meningitis is also recommended if you're travelling to areas at risk. Large outbreaks of meningococcal disease have been linked to the Hajj and Umrah pilgrimages. So it’s very important for pilgrims participating in Hajj or Umrah to get vaccinated with the MenACWY vaccine before travel.

Read more about vaccination for Hajj and Umrah pilgrims.

Are meningococcal vaccines safe?

Yes, all vaccines undergo extensive testing before they are licensed. When a vaccine is licensed, it means that experts have assessed the vaccine for safety and how well it works. Vaccine safety is then closely monitored during use. Clinical trial data shows the vaccines are safe and effective.3 They also have an excellent safety record since their introduction in routine immunisation programmes.4

You may experience minor side effects following vaccination. These symptoms are usually mild and go away on their own within a few days.

Common side effects of meningococcal vaccines include:

  • Irritability, crying, restlessness.
  • Loss of appetite.
  • Headache.
  • Pain, redness and swelling at the injection site.
  • Feeling tired (fatigue).
  • Mild fever.
Fever is common in babies when the MenB vaccine is given with other routine infant vaccines. In the UK, it’s recommended to give infants paracetamol soon after the MenB vaccine. This reduces the risk of fever and other side effects.5

Meningococcal meningitis is a severe and life-threatening disease that can cause death within hours, so it’s important to get your children vaccinated.
 

Why is it important to take up meningococcal vaccines?

Meningococcal meningitis is the most common cause of bacterial meningitis globally.6 It can kill within 24 hours and can have a devastating impact on families and individuals. Even in countries with well-developed healthcare systems around one in ten people who get it will die and as many as one in three survivors will be left with life-altering complications such as cognitive and psychological problems or disability, including hearing loss.7 Symptoms can be hard to spot and are similar to other common illnesses in the early stages. Prevention through vaccination is the best way to protect yourself and your family.

Meningococcal vaccines have saved many lives. The rollout of the MenA vaccine in the African meningitis belt has nearly eliminated group A meningococcal disease in the region and saved at least 2,000 lives.8 In the UK, meningococcal bacteria were once the leading cause of meningitis. But following the introduction of various meningococcal vaccination programmes, such as MenC, the teenage MenACWY programme and routine immunisation with MenB, there has been a dramatic decline in meningococcal meningitis across all age groups.9
 
Vaccination with conjugate meningococcal vaccines also protects the wider population from meningococcal disease. It stops people from carrying and spreading the bacteria.

For many years antibiotics have been used to treat meningococcal meningitis. But the meningococcal bacteria are finding new ways to resist antibiotics. This is known as antimicrobial resistance. Some groups of meningococcal bacteria have developed antimicrobial resistance in some areas of the world. Preventing meningococcal infections is key. It reduces the need to treat infections with antibiotics and therefore the chance of antimicrobial resistance.

Woman in an office speaking on the phone

Physical and emotional recovery from meningitis and its impact can be different for everyone. Support is available if meningitis has affected you or someone you know.

If you are in the UK or Ireland, the Meningitis Research Foundation Support Services team are ready to answer your questions.

If you are outside the UK and Ireland, our member network is the Confederation of Meningitis Organisations (CoMO). CoMO is dedicated to reducing the impact of meningitis globally, with members across the world. It is a great resource for finding support where you live.

Find a CoMO member in your country.

Frequently asked questions about meningococcal vaccines

Why should people have meningococcal vaccines?

People should get the meningococcal vaccines to protect themselves from meningitis and sepsis caused by meningococcal disease. Meningococcal disease is a serious, potentially life-threatening illness. It can affect anyone, but babies and children younger than five years old and teenagers are most at risk. The disease can cause lifelong disability and, in some cases, can be fatal. Vaccination is the best way to protect against it.

How do meningococcal vaccines work?

Meningococcal vaccines work by introducing a harmless piece of the bacteria (known as an antigen) into your body. This allows your immune system to recognise the bacteria and make protective antibodies against it. These antibodies then circulate in the bloodstream. If you come into contact with the bacteria you’ve been vaccinated against, the antibodies can destroy the bacteria before they can make you unwell.

At what age should people have their meningococcal vaccines?

The age at which people should get their meningococcal vaccines depends on the type of vaccine and where in the world you live.

In the UK and Ireland, the following vaccine schedule is recommended:
  • MenACWY is given to teenagers aged 13-15. A booster is given at age 16. If you miss the vaccine in school, you can get it up to age 25.
  • Men B is given to babies at 8 and 16 weeks with a booster aged one.
  • Men C is given to children aged 12-13 months (in the UK as a combined MenC/Hib vaccine).
You can check your country’s vaccination schedule on the WHO website.

How effective are meningococcal vaccines?

Meningococcal vaccines are effective at preventing meningococcal disease. Research has shown that polysaccharide vaccines are 65%–83.7% effective. Conjugate vaccines are 66%–100% effective in protecting against meningococcal disease.10

Meningococcal vaccines don’t protect against all groups of meningitis. So it’s important to be aware of the symptoms of meningitis even if you’ve been vaccinated.

Can meningococcal vaccines give you meningitis?

No, available meningococcal vaccines are not live vaccines. They cannot cause meningococcal meningitis. Instead, meningococcal vaccines contain antigens (harmless pieces of the bacteria). These trigger your body’s immune system and cause it to produce antibodies that attack and kill the bacteria.

How do I find out what meningococcal vaccines are available in my country?

You can find out what meningococcal vaccines are available in your country, and which age groups are eligible for vaccination, by checking the WHO’s national immunisation schedule data portal.
 
Not all vaccines are available to everyone, and not all meningococcal disease is vaccine-preventable. So awareness of the symptoms is vital.

A.
  1. Peterson, M. E., Li, Y., Bita, A., Moureau, A., Nair, H., Kyaw, M. H., Meningococcal Surveillance Group (in alphabetical order), Abad, R., Bailey, F., Garcia, I. F., Decheva, A., Krizova, P., Melillo, T., Skoczynska, A., & Vladimirova, N. (2019). Meningococcal serogroups and surveillance: a systematic review and survey. Journal of global health, 9(1), 010409. https://doi.org/10.7189/jogh.09.010409
  2. https://iris.who.int/bitstream/handle/10665/375623/WER9901-02-eng-fre.pdf?sequence=1
  3. Pizza, M., Bekkat-Berkani, R., & Rappuoli, R. (2020). Vaccines against Meningococcal Diseases. Microorganisms8(10), 1521. https://doi.org/10.3390/microorganisms8101521
  4. Marshall, G. S., Abbing-Karahagopian, V., Marshall, H. S., Cenci, S., Conway, J. H., Occhipinti, E., Bekkat-Berkani, R., Banzhoff, A., & Sohn, W. Y. (2023). A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Expert review of vaccines22(1), 530–544. https://doi.org/10.1080/14760584.2023.2222015
  5. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1110220/UKHSA-paracetamol-MenB-2022.pdf
  6. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021). Seattle, United States: Institute for Health Metrics and Evaluation (IHME), (2024). Available from: https://www.healthdata.org/research-analysis/library/global-burden-disease-2021-findings-gbd-2021-study
  7. Viner, R. M., Booy, R., Johnson, H., Edmunds, W. J., Hudson, L., Bedford, H., Kaczmarski, E., Rajput, K., Ramsay, M., & Christie, D. (2012). Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. The Lancet. Neurology, 11(9), 774–783. https://doi.org/10.1016/S1474-4422(12)70180-1
  8. Shattock, A. J., Johnson, H. C., Sim, S. Y., Carter, A., Lambach, P., Hutubessy, R. C. W., Thompson, K. M., Badizadegan, K., Lambert, B., Ferrari, M. J., Jit, M., Fu, H., Silal, S. P., Hounsell, R. A., White, R. G., Mosser, J. F., Gaythorpe, K. A. M., Trotter, C. L., Lindstrand, A., O'Brien, K. L., … Bar-Zeev, N. (2024). Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet (London, England)403(10441), 2307–2316. https://doi.org/10.1016/S0140-6736(24)00850-X
  9. Subbarao, S., Ribeiro, S., Campbell, H., Okike, I., Ramsay, M. E., & Ladhani, S. N. (2023). Trends in laboratory-confirmed bacterial meningitis (2012-2019): national observational study, England. The Lancet regional health. Europe32, 100692. https://doi.org/10.1016/j.lanepe.2023.100692
  10. Helena De Oliveira, L., Jauregui, B., Carvalho, A. F., & Giglio, N. (2017). Impact and effectiveness of meningococcal vaccines: a review. Revista panamericana de salud publica = Pan American journal of public health41, e158. https://doi.org/10.26633/RPSP.2017.158
Author: Meningitis Research Foundation.
Reviewed by: Natalie King, Meningitis Research Foundation Ambassador.
Published: 7 April 2025.

Meningitis in your words: real-life stories

Meningitis affects millions of people, in all regions of the world. Through the bravery of sharing personal stories, we bring together people from every region of the world to support one another, so they are empowered to live a life beyond meningitis.
Type - Meningococcal
Age group - Adult 25-59
Outcome - Recovery with after effects

"I know that I was one of the lucky ones."
Type - Meningococcal
Age group - Young child 3-5
Outcome - Bereavement

"I never got to say goodbye to her. She was gone, just like that."
Type - Meningococcal
Age group - Teenager
Outcome - Bereavement

"I believe MaryJo would still be here if she'd been vaccinated."